Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
This study tests blood, urine, and tissue samples from liver transplant recipients to see if they can help detect kidney disease, organ rejection, and hepatitis C infection early. Early detection of these conditions could help doctors provide better care and prevent serious complications after transplant.
Key Objective:The trial tests whether these samples can identify kidney disease, organ rejection, and hepatitis C earlier than current methods, potentially improving outcomes for transplant recipients.
Who to Consider:Liver transplant recipients who want to help develop better ways to monitor their health and detect complications early should consider enrolling.
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages. CKD damage to the kidneys, AR and HCV all lower the body's ability to function properly. Early detection of these conditions could assist with successful treatment and possibly lead to less repeat organ transplants.
Eligibility Criteria
Inclusion Criteria: 1. Male and female recipients of all races, ≥18 years of age. 2. Patients undergoing primary or subsequent living or deceased donor liver transplantation. 3. Subject and/or guardian must be able to provide informed consent. 4. Subject and/or guardian must be able to comply with the study protocol. Exclusion Criteria: 1\. Inability or unwillingness of a participant and/or guardian to provide informed consent.